Opportunities for Riboswitch Inhibition by Targeting Co-Transcriptional RNA Folding Events
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910495 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Christine Stephen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Riboswitch, RNA Folding. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Burroughs Wellcome Fund, National Science Foundation.
Abstract (Originalsprache)
Antibiotic resistance is a critical global health concern, causing millions of prolonged bacterial infections every year and straining our healthcare systems. Novel antibiotic strategies are essential to combating this health crisis and bacterial non-coding RNAs are promising targets for new antibiotics. In particular, a class of bacterial non-coding RNAs called riboswitches has attracted significant interest as antibiotic targets. Riboswitches reside in the 5′-untranslated region of an mRNA transcript and tune gene expression levels in cis by binding to a small-molecule ligand. Riboswitches often control expression of essential genes for bacterial survival, making riboswitch inhibitors an exciting prospect for new antibacterials. Synthetic ligand mimics have predominated the search for new riboswitch inhibitors, which are designed based on static structures of a riboswitch’s ligand-sensing aptamer domain or identified by screening a small-molecule library. However, many small-molecule inhibitors that bind an isolated riboswitch aptamer domain with high affinity in vitro lack potency in vivo. Importantly, riboswitches fold and respond to the ligand during active transcription in vivo. This co-transcriptional folding is often not considered during inhibitor design, and may explain the discrepancy between a low Kd in vitro and poor inhibition in vivo. In this review, we cover advances in riboswitch co-transcriptional folding and illustrate how intermediate structures can be targeted by antisense oligonucleotides—an exciting new strategy for riboswitch inhibitor design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA.
Förderung
- NIGMS NIH HHS
- Burroughs Wellcome Fund
- National Science Foundation
- National Institute of Health
- National Institutes of Health
- Burroughs Wellcome Fund CASI
Zitieren
APA
Stephen, C., Palmer, D., & Mishanina, T. V. (2024). Opportunities for Riboswitch Inhibition by Targeting Co-Transcriptional RNA Folding Events. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910495
Vancouver
Stephen C, Palmer D, Mishanina TV. Opportunities for Riboswitch Inhibition by Targeting Co-Transcriptional RNA Folding Events. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910495
BibTeX
@article{Stephen2024,
author = {Stephen, Christine and Palmer, Danea and Mishanina, Tatiana V},
title = {Opportunities for Riboswitch Inhibition by Targeting Co-Transcriptional RNA Folding Events},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910495}
}
EUVIMED